Роль бета-герпес-вирусов 6a и 6b в патогенезе рассеянного склероза: современный взгляд на проблему

Роль вируса герпеса человека 6A и вируса герпеса человека 6B в патогенезе рассеянного склероза остается предметом дискуссий, что во многом обусловлено мультифакторной природой заболевания. В данном обзоре систематизированы данные о потенциальном влиянии вирусов герпеса человека 6A и 6B на возникновение и/ или развитие рассеянного склероза. Приведены факты обнаружения лабораторно-диагностических маркеров рассматриваемых бета-герпес-вирусов у пациентов с рассеянным склерозом. Описаны гипотетические механизмы патогенеза рассеянного склероза при участии вирусов герпеса человека 6A и 6B (молекулярная мимикрия, включение белков клетки-хозяина), в том числе в виде микст-инфекции с другими вирусами. Рассмотрены механизмы активации иммунной системы и развития нейровоспаления при воздействии данных бетагерпес-вирусов. Описаны основные проблемы, нерешенные вопросы и направления для будущих исследований в контексте роли вирусов герпеса человека 6A и 6B как участников патогенеза рассеянного склероза.

1. Попкова М.И., Уткин О.В., Брызгалова Д.А. Сравнительная характеристика бета-герпес-вирусов человека 6А и 6В. Современный взгляд на проблему. Журнал инфектологии. 2021;13(3):5-18. doi:10.22625/2072-6732-2021-13-3-5-18.

2. Yamanishi K, Okuno T, Shiraki K, et al. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet. 1988;1(8594):1065-1067. doi:10.1016/s01406736(88)91893-4.

3. Lundstr m W, Gustafsson R. Human Herpesvirus 6A Is a Risk Factor for Multiple Sclerosis. Frontiers in Immunology. 2022;13:840753. doi:10.3389/fimmu.2022.840753.

4. Садовничук Е.А., Топузова М.П., Малько В.А., Щербакова О.А., Бисага Г.Н. Рассеянный склероз: механизмы нейродегенерации. Инструментально выявляемые маркеры нейродегенерации. Российский нейрохирургический журнал им. проф. А.Л. Поленова. 2023;15(3):158-163. doi:10.56618/2071–2693_2023_15_3_158.

5. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46(4):907-911. doi:10.1212/wnl.46.4.907.

6. Park D.J. A unifying model for multiple sclerosis. Clinical and Experimental Medicine. 2025;25(1):133. doi:10.1007/s10238-025-01666-3.

7. Прокаева А.И., Архипов И.Е., Дорчинец Е.Е., Коробко Д.С., Малкова Н.А. Рассеянный склероз: современные диагностические маркеры и прогностические факторы прогрессирования. Сибирский научный медицинский журнал. 2024;44(1):39-51. doi:10.18699/SSMJ20240105.

8. Komaroff AL, Pellett PE, Jacobson S. Human Herpesviruses 6A and 6B in Brain Diseases: Association versus Causation. Clinical Microbiology Reviews. 2020;34(1):e00143-20. doi:10.1128/CMR.00143-20.

9. Challoner PB, Smith KT, Parker JD, et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America. 1995;92(16):7440-7444. doi:10.1073/pnas.92.16.7440.

10. Goodman AD, Mock DJ, Powers JM, Baker JV, Blumberg BM. Human herpesvirus 6 genome and antigen in acute multiple sclerosis lesions. J Infect Dis. 2003;187(9):1365-1376. doi:10.1086/368172.

11. Cermelli C, Berti R, Soldan SS, et al. High frequency of human herpesvirus 6 DNA in multiple sclerosis plaques isolated by laser microdissection. J Infect Dis. 2003;187(9):1377-1387. doi:10.1086/368166.

12. Opsahl ML, Kennedy PG. Early and late HHV-6 gene transcripts in multiple sclerosis lesions and normal appearing white matter. Brain. 2005;128(3):516-527. doi:10.1093/brain/awh390.

13. Gustafsson R, Reitsma R, Strålfors A, Lindholm A, Press R, Fogdell-Hahn A. Incidence of human herpesvirus 6 in clinical samples from Swedish patients with demyelinating diseases. J Microbiol Immunol Infect. 2014;47(5):418-421. doi:10.1016/j.jmii.2013.03.009.

14. Tejada-Simon MV, Zang YC, Hong J, Rivera VM, Killian JM, Zhang JZ. Detection of viral DNA and immune responses to the human herpesvirus 6 101-kilodalton virion protein in patients with multiple sclerosis and in controls. J Virol. 2002;76(12):6147-6154. doi:10.1128/jvi.76.12.6147-6154.2002.

15. Alvarez-Lafuente R, Garc a-Montojo M, De Las Heras V, et al. Herpesviruses and human endogenous retroviral sequences in the cerebrospinal fluid of multiple sclerosis patients. Mult Scler. 2008;14(5):595-601. doi:10.1177/1352458507086425.

16. Franciotta D, Bestetti A, Sala S, et al. Broad screening for human herpesviridae DNA in multiple sclerosis cerebrospinal fluid and serum. Acta Neurol Belg. 2009;109(4):277-282.

17. Derfuss T, Hohlfeld R, Meinl E. Intrathecal antibody (IgG) production against human herpesvirus type 6 occurs in about 20% of multiple sclerosis patients and might be linked to a polyspecific B-cell response. J Neurol. 2005;252(8):968-971. doi:10.1007/s00415-005-0794-z.

18. Ablashi DV, Lapps W, Kaplan M, Whitman JE, Richert JR, Pearson GR. Human Herpesvirus-6 (HHV-6) infection in multiple sclerosis: a preliminary report. Mult Scler. 1998;4(6):490-496. doi:10.1177/135245859800400606.

19. Virtanen JO, Wohler J, Fenton K, Reich DS, Jacobson S. Oligoclonal bands in multiple sclerosis reactive against two herpesviruses and association with magnetic resonance imaging findings. Mult Scler. 2014;20(1):27-34. doi:10.1177/1352458513490545.

20. Leibovitch EC, Jacobson S. Evidence linking HHV-6 with multiple sclerosis: an update. Curr Opin Virol. 2014 Dec;9:127-33. doi:10.1016/j.coviro.2014.09.016.

21. Alvarez-Lafuente R, Garcia-Montojo M, De Las Heras V, Dominguez-Mozo MI, Bartolome M, Arroyo R. CD46 expression and HHV-6 infection in patients with multiple sclerosis. Acta Neurol Scand. 2009;120(4):246-250. doi:10.1111/j.16000404.2009.01163.x.

22. Ben-Fredj N, Ben-Selma W, Rotola A, et al. Prevalence of human herpesvirus U94/REP antibodies and DNA in Tunisian multiple sclerosis patients. J Neurovirol. 2013;19(1):42-47. doi:10.1007/s13365-012-0138-6.

23. Ramroodi N, Sanadgol N, Ganjali Z, Niazi AA, Sarabandi V, Moghtaderi A. Monitoring of active human herpes virus 6 infection in Iranian patients with different subtypes of multiple sclerosis. J Pathog. 2013;2013:194932. doi:10.1155/2013/194932.

24. Nejati A, Shoja Z, Farahmand M, et al. Human herpes virus 6 status in relapsing-remitting multiple sclerosis patients. Intern Med J. 2017;47(3):339-341. doi:10.1111/imj.13363.

25. Akhyani N, Berti R, Brennan MB, et al. Tissue distribution and variant characterization of human herpesvirus (HHV)-6: increased prevalence of HHV-6A in patients with multiple sclerosis. J Infect Dis. 2000;182(5):1321-1325. doi:10.1086/315893.

26. Simpson S Jr, Taylor B, Dwyer DE, et al. AntiHHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis. Mult Scler. 2012;18(6):799-806. doi:10.1177/1352458511428081.

27. Ortega-Madueño I, Garcia-Montojo M, Dominguez-Mozo MI, et al. Anti-human herpesvirus 6A/B IgG correlates with relapses and progression in multiple sclerosis. PLoS One. 2014;9(8):e104836. doi:10.1371/journal.pone.0104836.

28. Khaki M, Ghazavi A, Ghasami K, et al. Evaluation of viral antibodies in Iranian multiple sclerosis patients. Neurosciences (Riyadh). 2011;16(3):224-228.

29. Engdahl E, Gustafsson R, Huang J, et al. Increased Serological Response Against Human Herpesvirus 6A Is Associated With Risk for Multiple Sclerosis. Front Immunol. 2019;10:2715. doi:10.3389/fimmu.2019.02715.

30. Comabella M, Montalban X, Horga A, et al. Antiviral immune response in patients with multiple sclerosis and healthy siblings. Mult Scler. 2010;16(3):355-358. doi:10.1177/1352458509357066.

31. Voumvourakis KI, Kitsos DK, Tsiodras S, Petrikkos G, Stamboulis E. Human herpesvirus 6 infection as a trigger of multiple sclerosis. Mayo Clin Proc. 2010;85(11):1023-1030. doi:10.4065/mcp.2010.0350.

32. Voumvourakis KI, Fragkou PC, Kitsos DK, Foska K, Chondrogianni M, Tsiodras S. Human herpesvirus 6 infection as a trigger of multiple sclerosis: an update of recent literature. BMC Neurol. 2022;22(1):57. doi:10.1186/s12883-022-02568-7.

33. Pormohammad A, Azimi T, Falah F, Faghihloo E. Relationship of human herpes virus 6 and multiple sclerosis: A systematic review and meta-analysis. J Cell Physiol. 2018;233(4):2850-2862. doi:10.1002/jcp.26000.

34. Khalesi Z, Tamrchi V, Razizadeh MH, et al. Association between human herpesviruses and multiple sclerosis: A systematic review and meta-analysis. Microb Pathog. 2023;177:106031. doi:10.1016/j.micpath.2023.106031.

35. Vitturi BK, Cellerino M, Boccia D, et al. Environmental risk factors for multiple sclerosis: a comprehensive systematic review and meta-analysis. J Neurol. 2025;272(8):513. doi:10.1007/s00415-025-13248-0.

36. Tejada-Simon MV, Zang YC, Hong J, Rivera VM, Zhang JZ. Cross-reactivity with myelin basic protein and human herpesvirus-6 in multiple sclerosis. Ann Neurol. 2003;53(2):189-197. doi:10.1002/ana.10425.

37. Cheng W, Ma Y, Gong F, et al. Cross-reactivity of autoreactive T cells with MBP and viral antigens in patients with MS. Front Biosci (Landmark Ed). 2012;17(5):1648-1658. doi:10.2741/4010.

38. Dunn N, Kharlamova N, Fogdell-Hahn A. The role of herpesvirus 6A and 6B in multiple sclerosis and epilepsy. Scand J Immunol. 2020;92(6):e12984. doi:10.1111/sji.12984.

39. Mechelli R, Romano C, Reni R, et al. Viruses and neuroinflammation in multiple sclerosis. Neuroimmunol Neuroinflammation. 2021;8:269-83. doi:10.20517/2347-8659.2021.01.

40. Mock DJ, Strathmann F, Blumberg BM, Mayer-Proschel M. Infection of murine oligodendroglial precursor cells with Human Herpesvirus 6 (HHV-6)--establishment of a murine in vitro model. J Clin Virol. 2006;37(1):17-23. doi:10.1016/S13866532(06)70006-3.

41. Sedighi S, Gholizadeh O, Yasamineh S, et al. Comprehensive Investigations Relationship Between Viral Infections and Multiple Sclerosis Pathogenesis. Curr Microbiol. 2022;80(1):15. doi:10.1007/s00284-022-03112-z.

42. Donati D. Viral infections and multiple sclerosis. Drug Discov Today Dis Models. 2020;32:27-33. doi:10.1016/j.ddmod.2020.02.003.

43. Reynaud JM, Jégou JF, Welsch JC, Horvat B. Human herpesvirus 6A infection in CD46 transgenic mice: viral persistence in the brain and increased production of proinflammatory chemokines via Toll-like receptor 9. J Virol. 2014;88(10):54215436. doi:10.1128/JVI.03763-13.

44. Leibovitch E, Wohler JE, Cummings Macri SM, et al. Novel marmoset (Callithrix jacchus) model of human Herpesvirus 6A and 6B infections: immunologic, virologic and radiologic characterization. PLoS Pathog. 2013;9(1):e1003138. doi:10.1371/journal.ppat.1003138.

45. Yao K, Graham J, Akahata Y, Oh U, Jacobson S. Mechanism of neuroinflammation: enhanced cytotoxicity and IL-17 production via CD46 binding. J Neuroimmune Pharmacol. 2010;5(3):469-478. doi:10.1007/s11481-010-9232-9.

46. Keyvani H, Zahednasab H, Aljanabi HAA, et al. The role of human herpesvirus-6 and inflammatory markers in the pathogenesis of multiple sclerosis. J Neuroimmunol. 2020;346:577313. doi:10.1016/j.jneuroim.2020.577313.

47. Meeuwsen S, Persoon-Deen C, Bsibsi M, et al. Modulation of the cytokine network in human adult astrocytes by human herpesvirus-6A. J Neuroimmunol. 2005;164(1-2):37-47. doi:10.1016/j.jneuroim.2005.03.013.

48. Soldan SS, Fogdell-Hahn A, Brennan MB, et al. Elevated serum and cerebrospinal fluid levels of soluble human herpesvirus type 6 cellular receptor, membrane cofactor protein, in patients with multiple sclerosis. Ann Neurol. 2001;50(4):486-493. doi:10.1002/ana.1135.

49. Fogdell-Hahn A, Soldan SS, Shue S, et al. Co-purification of soluble membrane cofactor protein (CD46) and human herpesvirus 6 variant A genome in serum from multiple sclerosis patients. Virus Res. 2005;110(1-2):57-63. doi:10.1016/j.virusres.2005.01.005.

50. Wuest SC, Mexhitaj I, Chai NR, et al. A complex role of herpes viruses in the disease process of multiple sclerosis. PLoS One. 2014;9(8):e105434. doi:10.1371/journal.pone.0105434.

51. Soldan SS, Leist TP, Juhng KN, McFarland HF, Jacobson S. Increased lymphoproliferative response to human herpesvirus type 6A variant in multiple sclerosis patients. Ann Neurol. 2000;47(3):306-313.

52. Fotheringham J, Williams EL, Akhyani N, Jacobson S. Human herpesvirus 6 (HHV-6) induces dysregulation of glutamate uptake and transporter expression in astrocytes. J Neuroimmune Pharmacol. 2008;3(2):105-116. doi:10.1007/s11481007-9084-0.

53. Matute C, Alberdi E, Domercq M, P rez-Cerd F, P rezSamart n A, S nchez-G mez MV. The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci. 2001;24(4):224-230. doi:10.1016/s01662236(00)01746-x.

54. Campbell A, Hogestyn JM, Folts CJ, et al. Expression of the Human Herpesvirus 6A Latency-Associated Transcript U94A Disrupts Human Oligodendrocyte Progenitor Migration. Sci Rep. 2017;7(1):3978. doi:10.1038/s41598-017-04432-y.

55. Kong H, Baerbig Q, Duncan L, Shepel N, Mayne M. Human herpesvirus type 6 indirectly enhances oligodendrocyte cell death. J Neurovirol. 2003;9(5):539-550. doi:10.1080/13550280390241241.

56. Gardell JL, Dazin P, Islar J, Menge T, Genain CP, Lalive PH. Apoptotic effects of Human Herpesvirus-6A on glia and neurons as potential triggers for central nervous system autoimmunity. J Clin Virol. 2006;37(1):11-16. doi:10.1016/S13866532(06)70005-1.

57. Gustafsson R. Human Herpesvirus 6A Induces Dendritic Cell Death and HMGB1 Release without Virus Replication. Pathogens. 2021;10(1):57. doi:10.3390/pathogens10010057.

58. Paudel YN, Angelopoulou E, C BK, Piperi C, Othman I. High mobility group box 1 (HMGB1) protein in Multiple Sclerosis (MS): Mechanisms and therapeutic potential. Life Sci. 2019;238:116924. doi:10.1016/j.lfs.2019.116924.

59. Grut V, Biström M, Salzer J, et al. Human herpesvirus 6A and axonal injury before the clinical onset of multiple sclerosis. Brain. 2024;147(1):177-185. doi:10.1093/brain/awad374.

60. Tao C, Simpson-Yap S, Taylor B, et al. Markers of Epstein-Barr virus and Human Herpesvirus-6 infection and multiple sclerosis clinical progression. Mult Scler Relat Disord. 2022;59:103561. doi:10.1016/j.msard.2022.103561.

61. Censi ST, Mariani-Costantini R, Granzotto A, Tomassini V, Sensi SL. Endogenous retroviruses in multiple sclerosis: A network-based etiopathogenic model. Ageing Res Rev. 2024;99:102392. doi:10.1016/j.arr.2024.102392.

62. Charvet B, Reynaud JM, Gourru-Lesimple G, Perron H, Marche PN, Horvat B. Induction of Proinflammatory Multiple Sclerosis-Associated Retrovirus Envelope Protein by Human Herpesvirus-6A and CD46 Receptor Engagement. Front Immunol. 2018;9:2803. doi:10.3389/fimmu.2018.02803.

63. Flamand L, Menezes J. Cyclic AMP-responsive element-dependent activation of Epstein-Barr virus zebra promoter by human herpesvirus 6. J Virol. 1996;70(3):1784-1791. doi:10.1128/JVI.70.3.1784-1791.1996.

64. Cuomo L, Angeloni A, Zompetta C, et al. Human herpesvirus 6 variant A, but not variant B, infects EBV-positive B lymphoid cells, activating the latent EBV genome through a BZLF-1-dependent mechanism. AIDS Res Hum Retroviruses. 1995;11(10):1241-1245. doi:10.1089/aid.1995.11.1241.

65. Turcanova VL, Bundgaard B, H llsberg P. Human herpesvirus-6B induces expression of the human endogenous retrovirus K18-encoded superantigen. J Clin Virol. 2009;46(1):15- 19. doi:10.1016/j.jcv.2009.05.015.

66. Fierz W. Multiple sclerosis: an example of pathogenic viral interaction?. Virol J. 2017;14(1):42. doi:10.1186/s12985017-0719-3.

67. Cree BAC. Herpes viral infection and the multiple sclerosis prodrome: is HHV-6A infection a second hit?. Brain. 2024;147(1):7-9. doi:10.1093/brain/awad418.

68. Gough KL, Anderson TK, Whiley DM, Sweeney EL. The diagnostic complexities of human herpesvirus 6 (HHV6) infections. J Clin Virol. 2025;182:105905. doi: 10.1016/j.jcv.2025.105905.

69. Peddu V, Dubuc I, Gravel A, et al. Inherited Chromosomally Integrated Human Herpesvirus 6 Demonstrates Tissue-Specific RNA Expression In Vivo That Correlates with an Increased Antibody Immune Response. J Virol. 2019;94(1):e01418-19. doi:10.1128/JVI.01418-1.

70. Филатова Е.Н., Сахарнов Н.А., Суслов Н.А., Попкова М.И., Уткин О.В. Первые данные о молекулярно-генетическом разнообразии ВГЧ6В и его влиянии на клинико-лабораторное течение мононуклеозоподобного синдрома у детей. Инфекция и иммунитет. 2025;15(3):476-488. doi:10.15789/2220-7619-FDO-17827.